

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemophilia b | D002836 | — | D67 | 1 | — | 3 | 1 | 4 | 9 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | 1 | — | 2 | 1 | 3 | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | — | — | — | — | 1 | 1 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | — | 1 | 1 |
| Hemorrhagic disorders | D006474 | — | D69.9 | — | — | — | — | 1 | 1 |
| Coagulation protein disorders | D020147 | — | — | — | — | — | — | 1 | 1 |
| Drug common name | Eftrenonacog alfa |
| INN | eftrenonacog alfa |
| Description | Alprolix (eftrenonacog alfa) is a fusion protein pharmaceutical. Eftrenonacog alfa was first approved as Alprolix on 2016-05-12. It has been approved in Europe to treat hemophilia b. |
| Classification | Fusion protein |
| Drug class | Fc fusion protein |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4594598 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 02E00T2QDE (ChemIDplus, GSRS) |

